Measure non-fasting full lipid profile (total cholesterol, HDL-C, non-HDL-C, triglycerides) and HbA1c as part of an initial baseline assessment. Consider secondary causes of hyperlipidaemia and manage as needed. Ensure appropriate baseline and follow up tests as detailed on page 2.
2022 ACC Expert Consensus Decision Pathway on the Role of …
2022年8月25日 · To reflect newer information on the use of ezetimibe therapy as an adjunct to statin therapy in higher-risk patients, the ACC published the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk (denoted as the 2016 ACC ...
Low-density lipoprotein cholesterol-lowering therapy in the ... - UpToDate
2024年6月27日 · Lowering low-density lipoprotein cholesterol (LDL-C) can reduce the risk of atherosclerotic cardiovascular disease (CVD) in people without established CVD. This approach to CVD prevention is called primary prevention.
Statins: Actions, side effects, and administration - UpToDate
2024年4月23日 · The major adverse reaction limiting statin use is the development of muscle symptoms, a condition known as statin-associated muscle symptoms (SAMS). This problem, including predisposing drug interactions, is discussed in detail separately.
Step 1: Consider up-titration of statin to a maximum dose atorvastatin 80mg (alternative is rosuvastatin 20mg to 40mg)*- see HIS table page 8 and consider dose-limitations in CKD (eGFR<30ml/min) Step 2: If intolerant to higher dose of statin, consider adding ezetimibe 10mg daily (SPC- check contra-indications) to maximal tolerated statin
Summary of national guidance for lipid management - NHS …
2020年4月9日 · A summary of national guidance for lipid management for primary and secondary prevention of cardiovascular disease (CVD), updated to take account of NICE NG238, Cardiovascular disease: risk assessment and reduction, including lipid modification (published 14 December 2023).
HMG-CoA Reductase Inhibitors - StatPearls - NCBI Bookshelf
2023年7月3日 · HMG-CoA reductase inhibitors (statins) are lipid-lowering medications used in the primary and secondary prevention of coronary heart disease. This activity reviews the indications, contraindications, and mechanism of action of statins for the management of coronary heart disease and familial dyslipidemias.
• Statins are the cornerstone for prevention and treatment of cardiovascular (CV) disease with a substantial evidence of reduction of morbidity and mortality. Refer to Lipid Management Pathway and related NICE guidelines (CG181, CG71) for guidance on …
Statins Do More Than Lower Cholesterol—Depending on What …
2021年5月3日 · Consistent evidence indicates that these LDL cholesterol–lowering effects of statins account for their proven efficacy in reducing the risk of adverse cardiovascular outcomes and death. Figure. Simplified scheme of the synthesis pathway of …
Mechanisms and regulation of cholesterol homeostasis
2019年12月17日 · In this Review, we discuss the latest advances regarding how each of the four parts of cholesterol metabolism is executed and regulated. The key factors governing these pathways and the major...